Eli Lilly and Company LLY shares gained 3.8% on Wednesday after the company announced the FDA approval of its oral GLP-1 drug, orforglipron, for adults with obesity or overweight with weight-related ...
Eli Lilly (LLY) stock dropped 3% on Foundayo liver concerns. Analysts say the decline is overdone and recommend buying the ...
Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite ...
Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when the ...
Stocktwits on MSN
LLY stock in spotlight after Wall Street reaffirms confidence post FDA adverse event flag
According to TheFly, Eli Lilly told Wolfe Research that, in line with its standard procedures, Lilly Global Patient Safety ...
The fund, under normal market conditions, will invest at least 80% of its net assets (plus any borrowings for investment purposes) in shares of LLY, investments that provide exposure to LLY or ...
And what's remarkable is that Lilly’s biopharma competitors don't own the size of a franchise in obesity drugs as compared to Lilly or Novo. Companies like Pfizer (PFE) have made headlines recently as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results